PT  - JOURNAL ARTICLE
AU  - Raveendran, Ciniraj
AU  - Sunaisha Ashrafudeen, Sherin
AU  - Yadev, IP
TI  - Bortezomib-induced neuropathy in multiple myeloma manifesting as foot drop due to peroneal nerve palsy
AID  - 10.1136/bcr-2024-260909
DP  - 2024 Sep 01
TA  - BMJ Case Reports
PG  - e260909
VI  - 17
IP  - 9
4099  - http://casereports.bmj.com/content/17/9/e260909.short
4100  - http://casereports.bmj.com/content/17/9/e260909.full
SO  - BMJ Case Reports2024 Sep 01; 17
AB  - We present the case of a man in his 50s with multiple myeloma who developed foot drop after receiving bortezomib-dexamethasone combination chemotherapy. Diagnostic evaluations, including haematological parameters, nerve conduction studies and imaging, were performed to confirm the diagnosis and assess the extent of neuropathy. He was managed conservatively with analgesics and vitamin supplements, and bortezomib was temporarily withheld. The neuropathy gradually improved, and bortezomib was successfully reintroduced without recurrence of foot drop. Bortezomib-induced foot drop is a rare complication of bortezomib-based therapy in patients with multiple myeloma. Early recognition and intervention are crucial to minimise impact on quality of life. This case report emphasises the safe reintroduction of bortezomib post-neuropathy resolution, emphasising the importance of early recognition and multidisciplinary management.